Dirk Schnappinger

Cornell University — United States

Medicine · Health Sciences

56h-index15.7kcitations190works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(118), Mycobacterium research and diagnosis(68), Biochemical and Molecular Research(40), RNA and protein synthesis mechanisms(28), Antibiotic Resistance in Bacteria(25)

Publications190 total

Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against <i>Mycobacterium tuberculosis</i>
2026Open Access
Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials
The Lancet Microbe·2026· 1 citedOpen Access
Chlorotonils exhibit potent activity against <i>Mycobacterium tuberculosis</i> , while resistance is mediated by MmpR5-MmpL5
2025
Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase
Journal of Medicinal Chemistry·2025Open Access
Reference-based chemical-genetic interaction profiling to elucidate small molecule mechanism of action in Mycobacterium tuberculosis
Nature Communications·2025· 1 citedOpen Access
Structure−Activity Relationship and Antituberculosis Properties of 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 Inhibitors
2025
Structure-Guided Development of a Potent BioA Inhibitor Validates Biotin Synthesis Inhibition as a Therapeutic Strategy for Tuberculosis
2025Open Access
Common Biological Properties of <i>Mycobacterium tuberculosis</i> MmpL3 Inhibitors
ACS Infectious Diseases·2025· 4 citedOpen Access
Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in <i>Mycobacterium tuberculosis</i>
Antimicrobial Agents and Chemotherapy·2025· 1 citedOpen Access
Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis
Journal of Medicinal Chemistry·2025Open Access
SuFEx-based antitubercular compound irreversibly inhibits Pks13
Nature·2025· 7 cited
Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action
Cell Systems·2025Open Access
A periplasmic protein complex supports arabinofuranosyltransferase activity and mediates intrinsic drug resistance in <i>Mycobacterium tuberculosis</i>
2025· 1 citedOpen Access
The <i>Mycobacterium tuberculosis</i> Transposon Sequencing Database (<scp>MtbTnDB</scp>): A Large‐Scale Guide to Genetic Conditional Essentiality
Molecular Microbiology·2025· 1 citedOpen Access
Mycobacterial EtfD contains an unusual linear [3Fe-4S] cluster and enables β-oxidation to drive proton pumping by the electron transport chain
2025Open Access
Breaking Barriers in Tuberculosis: Interview with Dirk Schnappinger
EMJ Microbiology & Infectious Diseases·2025Open Access
Design and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis
2025· 1 citedOpen Access
The <i>Mycobacterium tuberculosis</i> long-chain fatty acid resistome reveals the universal stress protein TB15.3 as essential for infection
2025Open Access
Common biological features of <i>Mycobacterium tuberculosis</i> MmpL3 inhibitors
2025· 1 citedOpen Access
Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of <i>Mycobacterium tuberculosis</i>
ACS Infectious Diseases·2025· 2 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Sabine Ehrt(30), Kyu Y. Rhee(9), Carl Nathan(8), Clifton E. Barry(7), Helena I. Boshoff(7), Gary K. Schoolnik(7), Joshua B. Wallach(7), Eric J. Rubin(6), Carolina Trujillo(6), Wolfgang Hillen(5), Curtis A. Engelhart(5), Martin I. Voskuil(4), Michael A. DeJesus(4), Sae Woong Park(4), Christopher M. Sassetti(4), Thomas R. Ioerger(4), Kévin Pethe(4), Kathryn O’Brien(4), Véronique Dartois(3), Jeremy M. Rock(3)